Table 2.

Cancer status and follow-up histology score

Follow-up histology score in subjects with incident or prevalent lung SCC or adenocarcinoma vs. subjects without associated lung cancer
ComparisonNaDifference in follow-up HSb95% CIP
SCC vs. No CA90–1,0220.820.32–1.320.001
Adenocarcinoma vs. No CA19–1,0220.10−0.96–1.160.855
SCC vs. Adenocarcinoma90–190.72−0.44–1.880.221
Follow-up histology scores from subjects with prevalent lung SCC or adenocarcinoma vs. subjects without associated lung cancer
Prevalent lung cancer vs. no cancerNaDifference in follow-up HSb95% CIP
Prevalent SCC vs. No CA65–10220.730.17–1.290.011
Prevalent Adenocarcinoma vs. No CA16–10220.01−1.04–1.050.999
Follow-up histology scores from subjects with incident lung SCC vs. subjects without associated lung cancer
SCC vs. no lung cancerNaDifference in follow-up HSb95% CIP
Incident SCC, All vs. No CA61–10221.550.80–2.30<0.001
Incident SCC, No prior CA vs. No CA30–10220.990.08–1.900.034

NOTE: Differences in follow-up histology scores (HS) as compared with cases without known lung cancer (No CA) for all prevalent or incident lung cancer cases, prevalent lung cancer cases alone, or incident SCC cases alone.

  • aNumber of biopsies (N) for each of the comparator groups, respectively.

  • bData for all analyses are adjusted for baseline diagnosis and tobacco parameters in the multivariable linear mixed effects model.